Sugi Predict

Sugi Predict / Compounds / SCHEMBL2409907

SCHEMBL2409907

SCHEMBL2409907

NC(=NO)C1CCCCC1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.45
▸ MAPK1 P28482 1/20 0.45
▸ HTT P42858 1/20 0.45
▸ NOS2 P35228 2/20 0.43
▸ CES2 O00748 1/20 0.39
▸ CES1 P23141 1/20 0.39
▸ CTSK P43235 1/20 0.38
▸ SIGMAR1 Q99720 1/20 0.37
▸ MGLL Q99685 1/20 0.35
▸ HDAC8 Q9BY41 1/20 0.33
▸ HDAC6 Q9UBN7 1/20 0.33
▸ TSHR P16473 2/20 0.32
▸ RECQL P46063 1/20 0.32
▸ EPHX1 P07099 2/20 0.32
▸ ALDH1A1 P00352 1/20 0.32
▸ GAA P10253 1/20 0.31
▸ RAB9A P51151 1/20 0.30
▸ ATM Q13315 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13492517 1.00 LMNA (0.45) LMNAMAPK1HTTNOS2CES2
SCHEMBL20124235 1.00 LMNA (0.45) LMNAMAPK1HTTNOS2CES2
SCHEMBL16199449 1.00 LMNA (0.45) LMNAMAPK1HTTNOS2CES2
SCHEMBL12824691 1.00 LMNA (0.45) LMNAMAPK1HTTNOS2CES2
SCHEMBL15508609 1.00 LMNA (0.45) LMNAMAPK1HTTNOS2CES2
SCHEMBL15599086 1.00 LMNA (0.45) LMNAMAPK1HTTNOS2CES2
SCHEMBL14400257 1.00 LMNA (0.45) LMNAMAPK1HTTNOS2CES2
SCHEMBL20124271 1.00 LMNA (0.45) LMNAMAPK1HTTNOS2CES2
SCHEMBL21255728 1.00 LMNA (0.45) LMNAMAPK1HTTNOS2CES2
SCHEMBL20124266 1.00 LMNA (0.45) LMNAMAPK1HTTNOS2CES2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250361263-A1 C17 POLAR-SUBSTITUTED HETEROAROMATIC SYNTHETIC TRITERPENOIDS AND METHODS OF USE THEREOF REATA PHARMACEUTICALS, INC. (US) 2025-11-27 — — US disclosed
EP-3999522-B1 C17 POLAR-SUBSTITUTED HETEROAROMATIC SYNTHETIC TRITERPENOIDS AND METHODS OF USE THEREOF REATA PHARMACEUTICALS INC (US) 2025-09-03 — — EP disclosed
US-12344631-B2 C17 polar-substituted heteroaromatic synthetic triterpenoids and methods of use thereof REATA PHARMACEUTICALS, INC. (US) 2025-07-01 — — US disclosed
CN-114641483-B C17 polar-substituted heteroaromatic synthetic triterpenes and methods of use thereof 里亚塔医药公司 2024-12-06 — — CN disclosed
US-20240132513-A1 BENZAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT AGENEBIO, INC. 2024-04-25 — — US disclosed
EP-3684357-B1 HETEROARYL ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS MERCK SHARP & DOHME LLC (US) 2022-12-28 — — EP disclosed
CN-114685505-A Imidazopyrrolopyridines as JAK family kinase inhibitors 詹森药业有限公司 2022-07-01 — — CN disclosed
CN-114641483-A C17 polar-substituted heteroaromatic synthetic triterpenoids and methods of use thereof 里亚塔医药公司 2022-06-17 — — CN disclosed
CN-109153649-B Allosteric modulators of nicotinic acetylcholine receptors 默沙东公司 2022-04-19 — — CN disclosed
CN-110312719-B Imidazopyrrolopyridines as JAK family kinase inhibitors 詹森药业有限公司 2022-04-15 — — CN disclosed
WO-2016071216-A1 PIPERIDINYLPYRAZOLOPYRIMIDINONES AND THEIR USE BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-05-12 — — WO disclosed
EP-3013828-A1 BROMODOMAIN INHIBITORS AbbVie Inc. (US) 2016-05-04 — — EP disclosed
WO-2015047133-A1 NOVEL CHEMICAL COMPOUNDS (VARIANTS) AND THE USE THEREOF TO TREAT ONCOLOGICAL DISEASES ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "ОТЕЧЕСТВЕННЫЕ ФАРМАЦЕВТИЧЕСКИЕ ТЕХНОЛОГИИ" 2015-04-02 — — WO disclosed
WO-2014206150-A1 BROMODOMAIN INHIBITORS ABBVIE INC. (US) 2014-12-31 — — WO disclosed
US-8629277-B2 Styrenyl 1,2,4-oxadiazole compounds Piramal Enterprises Limited (IN) 2014-01-14 — — US disclosed
CN-103108867-A Oxadiazole compounds, their preparation and use PIRAMAL LIFE SCIENCES LTD 2013-05-15 — — CN disclosed
US-20130005771-A1 OXADIAZOLE COMPOUNDS, THEIR PREPARATION AND USE Piramal Enterprises Limited (IN) 2013-01-03 — — US disclosed
EP-2539327-A1 OXADIAZOLE COMPOUNDS, THEIR PREPARATION AND USE Piramal Enterprises Limited (IN) 2013-01-02 — — EP disclosed
US-20120015988-A1 Sulfone Compounds Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-01-19 — — US disclosed
WO-2011104680-A1 OXADIAZOLE COMPOUNDS, THEIR PREPARATION AND USE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-09-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130005771-A1 OXADIAZOLE COMPOUNDS, THEIR PREPARATION AND USE MCL1, OXA1L, ABL1 LMNA 2191/4885MAPK1 3437/4885HTT 3222/4885
US-12344631-B2 C17 polar-substituted heteroaromatic synthetic triterpenoids and methods of use thereof CYP11B1, CYP11B2, RORC LMNA 2649/4885MAPK1 1824/4885HTT 4432/4885
US-20120015988-A1 Sulfone Compounds Which Modulate The CB2 Receptor CNR2, CNR1, TRPV1 LMNA 4742/4885MAPK1 1511/4885HTT 4174/4885
US-20240132513-A1 BENZAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT GABRA5, GRM5, GABRB1 LMNA 1853/4885MAPK1 3867/4885HTT 1051/4885
US-20250361263-A1 C17 POLAR-SUBSTITUTED HETEROAROMATIC SYNTHETIC TRITERPENOIDS AND METHODS OF USE THEREOF CYP11B1, CYP11B2, RORC LMNA 2649/4885MAPK1 1824/4885HTT 4432/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.